US pharma giant Merck & Co opened Tuesday’s trading 10% lower after announcing its annual and fourth quarter financial ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Before the Senate's confirmation vote on President Donald Trump’s pick for secretary of the Department of Health and Human ...

Robert F. Kennedy Jr. has cleared his first hurdle to become the nation’s top health official as the Senate finance committee ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

(Reuters) - Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President Donald Trump's secretary of the U.S. Department of Health and ...

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

Merck desperately needs Moderna's mRNA-based ... days after CEO Stephane Bancel wrote in his Moderna 2024 Shareholder Letter that “There are positive signs going into 2025.” ...

the letter said. Kennedy and Baum did not immediately respond to requests for comment. Merck declined to comment. High-level U.S. government officials routinely disclose financial interests and ...